Clinical performance of 68Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy
Sensitive visualization of recurrent prostate cancer foci is a challenge in patients with early biochemical recurrence (EBR). The recently established 68Ga-PSMA-11 PET/CT has significantly improved the detection rate with published values of up to 55% for patients with a serum PSA concentration between 0.2–0.5 ng/mL. The increased soft tissue contrast in the pelvis using simultaneous 68Ga-PSMA-11 PET/MRI might further improve the detection rate in patients with EBR and low PSA values over PET/CT.
We retrospectively analyzed a cohort of 56 consecutive patients who underwent a 68Ga-PSMA-11 PET/MRI for biochemical recurrence in our institution between April and December 2016 with three readers. Median PSA level was 0.99 ng/mL (interquartile range: 3.1 ng/mL). Detection of PSMA-positive lesions within the prostate fossa, local and distant lymph nodes, bones, or visceral organs was recorded. Agreement among observers was evaluated with Fleiss’s kappa (k).
Overall, in 44 of 56 patients (78.6%) PSMA-positive lesions were detected. In four of nine patients (44.4%) with a PSA < 0.2 ng/mL, suspicious lesions were detected (two pelvic and one paraaortic lymph nodes, and two bone metastases). In eight of 11 patients (72.7%) with a PSA between 0.2 and < 0.5 ng/mL, suspicious lesions were detected (two local recurrences, six lymph nodes, and one bone metastasis). Five out of 20 patients with a PSA < 0.5 ng/mL had extrapelvic disease. In 12 of 15 patients (80.0%) with a PSA between 0.5 and < 2.0 ng/mL, suspicious lesions were detected (four local recurrences, nine lymph nodes, and four bone metastases). In 20 of 21 patients (95.2%) with a PSA >2.0 ng/mL, suspicious lesions were detected. The overall interreader agreement for cancer detection was excellent (κ = 0.796, CI 0.645–0.947).
Our data show that 68Ga-PSMA-11 PET/MRI has a high detection rate for recurrent prostate cancer even at very low PSA levels <0.5 ng/mL. Furthermore, even at those low levels extrapelvic disease can be localized in 25% of the cases and local recurrence alone is seen only in 10%.
KeywordsProstate cancer Prostate-specific antigen 68Ga-PSMA-11 Positron emission tomography PSMA antigen
The authors acknowledge Ms. Sarah Kedzia for the excellent organization of the patient database, and the technicians Marlena Hofbauer, Miguel Porto, Sofia Kaltsuni, Tobias Oblasser and Sabrina Epp for the excellent work on high quality PET/MRI.
Compliance with ethical standards
The Department of Nuclear Medicine holds an institutional Research Contract with GE Healthcare. The authors declare that no competing financial interests exist.
This retrospective study was approved by the local ethics committee (BASEC Nr. 2016–02230). All patients gave a written informed general consent for retrospective analysis of their data.
Authors IAB, MH and PAK have received research grants and speaker honorarium from GE Healthcare. Author IAB received research grants from Swiss Life and speaker honorarium from Bayer Health Care and Astellas Pharma AG. Author MG has received research grants from Varian. Authors BK, JM, ASB, PS, DE, HN, UM declare no conflict of interest.
- 2.Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2016; https://doi.org/10.1016/j.eururo.2016.08.003.
- 3.Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2016; https://doi.org/10.1016/j.eururo.2016.08.002.
- 4.Furubayashi N, Negishi T, Iwai H, Nagase K, Taguchi K, Shimokawa M, et al. Biochemical failure after radical prostatectomy in intermediate-risk group men increases with the number of risk factors. Indian J Urol. 2017;33:64–9. https://doi.org/10.4103/0970-1591.194786. PubMedPubMedCentralGoogle Scholar
- 8.Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, et al. Contemporary update of a multi-institutional predictive Nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. 2016; https://doi.org/10.1200/JCO.2016.67.9647.
- 9.Stish BJ, Pisansky TM, Harmsen WS, Davis BJ, Tzou KS, Choo R, et al. Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. J Clin Oncol. 2016; https://doi.org/10.1200/JCO.2016.68.3425.
- 10.Wiegel T, Lohm G, Bottke D, Hocht S, Miller K, Siegmann A, et al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study. Int J Radiat Oncol Biol Phys. 2009;73:1009–16. https://doi.org/10.1016/j.ijrobp.2008.06.1922.CrossRefPubMedGoogle Scholar
- 11.Robertson NL, Sala E, Benz M, Landa J, Scardino P, Scher HI, et al. Combined whole-body and multi-parametric prostate MRI as a single-step approach for the simultaneous assessment of local recurrence and metastatic disease after radical prostatectomy. J Urol. 2017; https://doi.org/10.1016/j.juro.2017.02.071.
- 12.Ceci F, Herrmann K, Castellucci P, Graziani T, Bluemel C, Schiavina R, et al. Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. Eur J Nucl Med Mol Imaging. 2014;41:2222–31. https://doi.org/10.1007/s00259-014-2872-x.CrossRefPubMedGoogle Scholar
- 13.Giovacchini G, Picchio M, Coradeschi E, Bettinardi V, Gianolli L, Scattoni V, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010;37:301–9. https://doi.org/10.1007/s00259-009-1253-3.CrossRefPubMedGoogle Scholar
- 14.Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197–209. https://doi.org/10.1007/s00259-014-2949-6.CrossRefPubMedGoogle Scholar
- 16.Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, et al. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun. 2015;36:582–7. https://doi.org/10.1097/MNM.0000000000000290.CrossRefPubMedGoogle Scholar
- 17.Einspieler I, Rauscher I, Duwel C, Kronke M, Rischpler C, Habl G, et al. Detection efficacy of hybrid 68Ga-PSMA ligand PET/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by phoenix criteria. J Nucl Med. 2017; https://doi.org/10.2967/jnumed.116.184457.
- 18.Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M, Eisenhut M, et al. Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41:887–97. https://doi.org/10.1007/s00259-013-2660-z.CrossRefPubMedGoogle Scholar
- 19.Freitag MT, Radtke JP, Afshar-Oromieh A, Roethke MC, Hadaschik BA, Gleave M, et al. Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. Eur J Nucl Med Mol Imaging. 2016; https://doi.org/10.1007/s00259-016-3594-z.
- 20.Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol. 2016; https://doi.org/10.1016/j.eururo.2015.12.053.
- 22.Ter Voert EE, Veit-Haibach P, Ahn S, Wiesinger F, Khalighi MM, Levin CS, et al. Clinical evaluation of TOF versus non-TOF on PET artifacts in simultaneous PET/MR: a dual centre experience. Eur J Nucl Med Mol Imaging. 2017; https://doi.org/10.1007/s00259-017-3619-2.
- 23.Svirydenka H, Delso G, Barbosa FG, Huellner MW, Davison H, Fanti S, et al. The effect of susceptibility artifacts related to metal implants on adjacent lesion assessment in simultaneous TOF PET/MR. J Nucl Med. 2017; https://doi.org/10.2967/jnumed.116.180802.
- 28.Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, et al. Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:70–83. https://doi.org/10.1007/s00259-015-3206-3.CrossRefPubMedGoogle Scholar
- 29.Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44:1258–68. https://doi.org/10.1007/s00259-017-3711-7.CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Fendler WP, Calais J, Allen-Auerbach M, Bluemel C, Eberhardt N, Emmett L, et al. 68Ga-PSMA-11 PET/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study. J Nucl Med. 2017; https://doi.org/10.2967/jnumed.117.190827.
- 31.Schiller K, Sauter K, Dewes S, Eiber M, Maurer T, Gschwend J, et al. Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after 68Ga-PSMA-PET imaging. Eur J Nucl Med Mol Imaging. 2017; https://doi.org/10.1007/s00259-017-3746-9.
- 32.Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Voo S, et al. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging. 2016;43:397–403. https://doi.org/10.1007/s00259-015-3240-1.CrossRefPubMedGoogle Scholar
- 33.Kabasakal L, Demirci E, Nematyazar J, Akyel R, Razavi B, Ocak M, et al. The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. Nucl Med Commun. 2016; https://doi.org/10.1097/MNM.0000000000000617.
- 34.Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11–20. https://doi.org/10.1007/s00259-013-2525-5.CrossRefPubMedGoogle Scholar
- 35.Pfob CH, Ziegler S, Graner FP, Kohner M, Schachoff S, Blechert B, et al. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:1962–70. https://doi.org/10.1007/s00259-016-3424-3.CrossRefPubMedGoogle Scholar
- 37.Uprimny C, Kroiss AS, Decristoforo C, Fritz J, Warwitz B, Scarpa L, et al. Early dynamic imaging in 68Ga- PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2017;44:765–75. https://doi.org/10.1007/s00259-016-3578-z.CrossRefPubMedGoogle Scholar
- 39.Lutje S, Blex S, Gomez B, Schaarschmidt BM, Umutlu L, Forsting M, et al. Optimization of acquisition time of 68Ga-PSMA-Ligand PET/MRI in patients with local and metastatic prostate cancer. PLoS One. 2016;11:e0164392. https://doi.org/10.1371/journal.pone.0164392.CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Derlin T, Weiberg D, von Klot C, Wester HJ, Henkenberens C, Ross TL, et al. 68Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol. 2016;26:4345–53. https://doi.org/10.1007/s00330-016-4308-4.CrossRefPubMedGoogle Scholar
- 42.Afshar-Oromieh A, Wolf M, Haberkorn U, Kachelriess M, Gnirs R, Kopka K, et al. Effects of arm truncation on the appearance of the halo artifact in 68Ga-PSMA-11 (HBED-CC) PET/MRI. Eur J Nucl Med Mol Imaging. 2017; https://doi.org/10.1007/s00259-017-3718-0.